<SEC-DOCUMENT>0001144204-18-062416.txt : 20181130
<SEC-HEADER>0001144204-18-062416.hdr.sgml : 20181130
<ACCEPTANCE-DATETIME>20181129194623
ACCESSION NUMBER:		0001144204-18-062416
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20181126
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181130
DATE AS OF CHANGE:		20181129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		181209612

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv507897_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>November 26, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B><U>ABEONA
THERAPEUTICS INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-15771</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of</FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1330 Avenue of the Americas, 33rd Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, NY 10019 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(646) 813-4712</U></B><BR>
(Registrant&rsquo;s telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 5.02.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective
November 26, 2018, Abeona Therapeutics, Inc. (the &ldquo;Company&rdquo;) terminated the employment of Frank Carsten Thiel,
Ph.D., its Chief Executive Officer. The termination by the Company was &ldquo;for Cause&rdquo; pursuant to the terms of the
Employment Agreement, dated March 29, 2018, between the Company and Dr. Thiel (the &ldquo;Employment Agreement&rdquo;). In
addition, on November 27, 2018, Dr. Thiel resigned as a member of the Board of Directors of the Company (the
 &ldquo;Board&rdquo;), effective immediately. Dr. Thiel&rsquo;s termination and resignation were due to conduct violating the
Company&rsquo;s Code of Business Conduct and Ethics and not related to the condition of the Company&rsquo;s
finances, operations or clinical programs, nor due to any disagreement with the Company regarding its management of
financial reporting, scientific data or other practices. On November 29, 2018, Dr. Thiel and the Company entered into a
separation agreement (the &ldquo;Separation Agreement&rdquo;) providing that he will only be entitled to receive, as of the
effective date of termination, Accrued Amounts and will recieve reimbursement for continuing medical benefits under COBRA for
six months or until he obtains health benefits through new employment, whichever is sooner, but will not otherwise be eligible
for any Annual Bonus or Severance Amount (each as defined in the Employment Agreement). The foregoing summary of the
Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by the full text of the
Separation Agreement, which is filed herewith as Exhibit 10.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective
November 26, 2018, the Board appointed Jo&atilde;o Siffert, M.D., 54, the Company&rsquo;s Head of Research and Development
and Chief Medical Officer, to serve as Interim Chief Executive Officer. Dr. Siffert will continue to oversee research and
development while serving as Interim Chief Executive Officer. It is anticipated that Dr. Siffert will serve as Interim
Chief Executive Officer until the election by the Board of a permanent chief executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection
with his appointment as Interim Chief Executive Officer, Dr. Siffert and the Company entered into an agreement (the
 &ldquo;Amendment&rdquo;) providing that he will receive an increased annualized salary of $550,000 (the &ldquo;Interim Base
Salary&rdquo;) in respect of a six-month period during which he is expected to serve in this position (the &ldquo;Interim
Period&rdquo;), commencing November 26, 2018. Other than the Interim Base Salary, Dr. Siffert&rsquo;s current agreement with
the Company, dated September 28, 2018 (the &ldquo;Current Agreement&rdquo;), will remain in place during the Interim Period.
Pursuant to the terms of the Current Agreement, Dr. Siffert will receive (i) a target bonus of 45% of his regular base
salary, $450,000, (ii) a sign-on bonus in the aggregate amount of $190,000, (iii) a grant of an initial option to purchase
180,000 shares of the Company&rsquo;s common stock, which option will vest over a 48 month period, with 25% vesting on the
one-year anniversary of the date of grant and the remaining 75% vesting in 36 equal monthly installments thereafter, and (iv)
a subsequent grant of an option to purchase 60,000 shares of the Company&rsquo;s common stock, which option will vest over a
48 month period with 25% vesting on the one-year anniversary of the date of grant and the remaining 75% vesting in 36
equal monthly installments thereafter. The foregoing summaries of the Current Agreement and the Amendment do not purport to
be complete and are subject to, and qualified in their entirety by the full text of these agreements, which are filed
herewith as Exhibits 10.1 and 10.2, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Siffert does
not have any family relationship with any member of the Board or any executive officer of the Company. Information about Dr.
Siffert&rsquo;s business experience can be found in the press release attached as Exhibit 99.1 hereto, which biographical
information contained in paragraph 5 thereof is incorporated into this Item 5.02 by reference. Aside from the Amendment
described in the preceding paragraph, there are no arrangements or understandings between Dr. Siffert and any other
person pursuant to which he was appointed to serve as the Company&rsquo;s Interim Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Siffert will not
serve on the Board of Directors during his tenure as Interim Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements
and Exhibits.</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(d) Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 88%"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv507897_ex10-1.htm">10.1 </A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv507897_ex10-1.htm">Letter Agreement between Abeona Therapeutics, Inc. and Jo&atilde;o Siffert, M.D.,
    dated September 28, 2018.</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv507897_ex10-2.htm">10.2</A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv507897_ex10-2.htm">Letter Agreement between Abeona Therapeutics, Inc. and
    Jo&atilde;o Siffert, M.D., dated November 29, 2018</A>.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv507897_ex10-3.htm" STYLE="-sec-extract: exhibit">10.3</A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv507897_ex10-3.htm" STYLE="-sec-extract: exhibit">Separation Agreement between Abeona Therapeutics, Inc. and F. Carsten Thiel, Ph. D.,
    dated November 29, 2018.</A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><A HREF="tv507897_ex99-1.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><A HREF="tv507897_ex99-1.htm"><FONT STYLE="font-size: 10pt">Press Release, dated November 26, 2018.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>SIGNATURE&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Abeona Therapeutics Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 12%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Neena Patil</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Neena Patil</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">General Counsel and Secretary </FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: November 29, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tv507897_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%; vertical-align: middle; text-align: left"><P STYLE="margin: 0pt 0">September 28, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></P>


</TD>
    <TD STYLE="width: 50%; text-align: right">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 91px; width: 264px"></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Joao Siffert, MD</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-indent: 294.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Joao,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">I am pleased
to offer you the position of Executive Vice President, Head of Research &amp; Development with Abeona Therapeutics Inc. (the &ldquo;<U>Company</U>&rdquo;)
reporting to our Chief Executive Officer (&ldquo;<U>CEO</U>&rdquo;), effective October 24, 2018 (the &quot;<U>Effective Date</U>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD><U>Duties</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As the Head of Research &amp; Development,
your general duties shall include, but not be limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Leadership of the Research &amp; Development (&ldquo;<U>R&amp;D</U>&rdquo;)
organization including oversight of the product development team (&ldquo;<U>Research</U>&rdquo;), Clinical Operations, Medical
Affairs and Regulatory Affairs</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Working with Business Development and Commercial to develop the preclinical
and clinical strategy</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Providing vision and plan for shaping the Company to delivering future
pipeline growth</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ensuring that work is conducted in compliance with Company guidelines
applicable laws and regulations and industry standards</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ensuring resource levels, competencies, skills and knowledge are in
place and balanced to support achievement of R&amp;D targets across R&amp;D</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Supporting of Bids &amp; Proposals work streams</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Accountable for budget, schedule, scope, quality and delivery of all
R&amp;D projects</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Building the delivery structure for R&amp;D projects</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Leading the R&amp;D team to meet the Company strategy through tasks
and project delivery</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Development and management of the R&amp;D Governance and Plans</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Establishing compliance tools, trainings and processes in your team</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Line management and career development responsibilities</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ensuring the department is using industry best practice in the delivery
of projects and products</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify; padding-right: 9.55pt"><U>Compensation and Benefits</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">During your
employment, you will receive a base salary of $450,000 USD, payable in accordance with the regular payroll practices of the Company
(&ldquo;<U>Base Salary</U>&rdquo;). During your employment, you may be considered for an annual discretionary bonus (&ldquo;<U>Annual
Bonus</U>&rdquo;) in addition to your Base Salary with a target of 45% of your Base Salary (&ldquo;<U>Target Annual Bonus Opportunity</U>&rdquo;).
Annual Bonus compensation in any year, if any, will be determined in the Company sole discretion and shall be based on your performance
and that of the Company, as well as market factors, in accordance with a general bonus program established by the Compensation
Committee (the &ldquo;<U>Compensation Committee</U>&rdquo;) of the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;).
Except as provided below under Section 3 in the event of certain terminations of your employment, to be eligible to receive an
Annual Bonus for any year, if any, you must be employed in good standing on the date that the Annual Bonus is paid. You will receive
a sign-on bonus of $ 190,000 USD with $95,000 paid within thirty (30) days following the Effective Date and $95,000 paid 120 days
after the Effective Date, provided you are employed on such dates. This sign-on bonus is to encourage you to accept employment
with the Company and is not payment for any work performed or services rendered by you. Your right to retain the sign-on bonus,
therefore, shall not vest until you have completed one (1) year of service with the Company. Accordingly, this sign-on bonus is
repayable immediately should your employment terminate for any reason, including your resignation, within one (1) year following
the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">Subject
to Compensation Committee approval, at the first regularly scheduled meeting of the Compensation Committee after the Effective
Date, you will be granted a stock option under the Abeona Therapeutics Inc. 2015 Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;)
to purchase 180,000 shares of Company common stock (the &quot;<U>Initial Option</U>&quot;). The Initial Option will vest over a
forty-eight (48) month period, with one quarter (25%) vesting on the one-year anniversary of the Effective Date and the remaining
seventy-five percent (75%) of the Initial Option vesting in equal monthly installments thereafter over the remaining thirty-six
(36) months, commencing with the first month following the first anniversary of the Effective Date, and subject to (i) your continued
employment with the Company and/or its affiliates through to the applicable vesting dates, and (ii) the terms and conditions of
the Plan and the agreement memorializing the terms of the Initial Option. If you remain continuously employed from the Effective
Date through the date of a Change in Control (as defined below), any unvested portion of the Initial Option as of the date of the
Change in Control shall become fully vested immediately prior to the date of the Change in Control. Pursuant to the terms of the
Plan, the exercise price of the Initial Option will be the fair market value of the Company&rsquo;s common stock on the date of
the grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">Subject
to Compensation Committee approval, in January 2019, you will be granted a stock option under the Plan to purchase 60,000 shares
of Company common stock (&quot;<U>Subsequent Option</U>&quot;). The Subsequent Option will vest over a forty-eight (48) month period,
with one quarter (25%) vesting on the one-year anniversary of the date of grant and the remaining seventy-five percent (75%) of
the Subsequent Option vesting in equal monthly installments thereafter over the remaining thirty-six (36) months, commencing with
the first month following the first anniversary of the date of grant, and subject to (i) your continued employment with the Company
and/or its affiliates through to the applicable vesting dates, and (ii) the terms and conditions of the Plan and the agreement
memorializing the terms of the Subsequent Option. If you remain continuously employed from the Effective Date through the date
of a Change in Control, any unvested portion of the Subsequent Option as of the date of the Change in Control shall become fully
vested immediately prior to the date of the Change in Control. Pursuant to the terms of the Plan, the exercise price of the Subsequent
Option will be the fair market value of the Company&rsquo;s common stock on the date of the grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">During your
employment, you will be eligible to participate in such health and other group insurance and other employee benefit plans and programs
of the Company as in effect from time to time on the same basis as other senior executives of the Company. Your participation will
be subject to the terms of the applicable plan documents and generally applicable Company policies. The Company reserves the right
to amend or terminate any employee benefit plans, programs and policies in its discretion after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">You will
be entitled to twenty (20) days of paid time off (vacation days plus sick time/personal time) per year accrued at a rate in accordance
with the Company&rsquo;s policies from time to time in effect, in addition to holidays observed by the Company. Paid time off may
be taken at such times and intervals as you shall determine, subject to the business needs of the Company and the responsibilities
of your position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify; padding-right: 9.55pt"><U>Employment Termination</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may terminate
your employment for any reason, and you may voluntarily terminate your employment hereunder for any reason, in each case at any
time upon written notice to the other party (the date on which your employment terminates for any reason is herein referred to
as the &ldquo;<U>Termination Date</U>&rdquo;). Upon your termination of employment for any reason, you (or your beneficiary or estate, as applicable, in the event of your death) will be entitled to (i) payment of any Base Salary earned
but unpaid through the Termination Date, (ii) any accrued unused vacation days, (iii) additional vested benefits (if any) in accordance
with the applicable terms of applicable Company arrangements, and (iv) any unreimbursed expenses in accordance with the Company&rsquo;s
business expense reimbursement policies (collectively, the &ldquo;<U>Accrued Amounts</U>&rdquo;); <U>provided</U>, <U>however</U>,
that if your employment hereunder is terminated (a) by the Company without Cause (as defined below), (b) by you for Good Reason
(as defined below), (c) on account of your death or (d) by the Company on account of your Disability (as defined below), then you
will be eligible to receive any Annual Bonus awarded in a prior year, but not yet paid or due to be paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If your employment
is terminated (a) by the Company other than for Cause, death or Disability or (b) by you for Good Reason, in addition to the Accrued
Amounts, you will be entitled to: (i) a payment equal to the sum of your Base Salary plus your Target Annual Bonus Opportunity
(such amount, the &ldquo;<U>Severance Amount</U>&rdquo;); (ii) a payment equal to the premiums that you would pay if you elected
continued health coverage under the Company&rsquo;s health plan for you and your eligible dependents for the twelve (12) month
period following the Termination Date, less the applicable active employee rate, which premiums will be calculated based on the
rate determined under the COBRA rate in effect on the Termination Date (&ldquo;<U>Medical Benefit Payment</U>&rdquo;); (iii) a
pro-rata Annual Bonus, which pro-rated Annual Bonus shall be determined by multiplying the full year Annual Bonus that would otherwise
have been awarded to you, based upon the achievement of the applicable performance goals for the year in which the Termination
Date occurs (without any exercise of negative discretion disproportionate to any such exercise respecting other executives and
all subjective performance requirements deemed fully satisfied), multiplied by a fraction, the numerator of which is the number
of days during which you were employed by the Company in the year in which the Termination Date occurs and the denominator of which
is three hundred sixty-five (365); and (iv) accelerated vesting equivalent to twelve (12) months of continued employment from the
Termination Date (disregarding such termination for such purpose) with respect to all unvested equity and any other long-term incentive
awards granted to you and then outstanding on the Termination Date; <U>provided</U>, <U>that</U>, any delays in the settlement
or payment of such awards that are set forth in the applicable award agreement and that are required under Section 409A of the
Internal Revenue Code, as amended (the &ldquo;<U>Code</U>&rdquo;), and the Treasury Regulations thereunder (&ldquo;<U>Section 409A</U>&rdquo;)
shall remain in effect. The Company&rsquo;s obligations to make the payments and provide the benefits set forth in (i) &ndash;
(iv) in this Paragraph shall be conditioned upon your continued compliance with your obligations under Section 4 below and your
execution and nonrevocation of a release of claims in favor of the Company and its affiliates in a form provided by the Company
(&ldquo;<U>Release</U>&rdquo;). Notwithstanding any provision to the contrary herein (other than the provisions of Section 7 below),
and without limitation of any remedies to which the Company may be entitled, (A) the Severance Amount shall be paid in installments
in accordance with the Company&rsquo;s regular payroll practices during a twelve (12) month period commencing within sixty (60)
days following the Termination Date (with the first such payment to include all installment amounts from the Termination Date),
(B) the Medical Benefit Payment will be made in a lump sum within sixty (60) days following the Termination Date and (C) the pro-rated
Annual Bonus shall be paid to you in the ordinary course at the same time annual bonuses are paid to other senior executives, but
in no event later than March 15 of the year following the year in which the Termination Date occurs; <U>provided</U>, <U>that</U>,
the Release is effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any
other provision contained herein, if your employment hereunder is terminated by you for Good Reason or by the Company without Cause
(other than on account of your death or Disability), in each case within twelve (12) months following a Change in Control, you
will be entitled to receive the Severance Amount, the Medical Benefit Payment, and the pro-rata Annual Bonus, as provided above,
except that (i) if the Change in Control is a &ldquo;change in control event&rdquo; as defined under Section 409A, the Severance
Amount shall be payable in a lump sum within sixty (60) days following the Termination Date; and (ii)&nbsp;notwithstanding the
terms of any equity incentive plan or award agreements, as applicable, all outstanding unvested stock options/stock appreciation
rights granted to your during your employment with the Company shall become fully vested and exercisable and will remain exercisable
for six (6) months following the Termination Date and all outstanding equity-based and other long-term compensation awards, other
than stock options/stock appreciation rights, shall become fully vested and the restrictions thereon shall lapse; <U>provided</U>,
<U>that</U>, any delays in the settlement or payment of such awards that are set forth in the applicable award agreement and that
are required under Section 409A shall remain in effect. The Company&rsquo;s obligations to provide the payments and benefits described
in this Paragraph shall be conditioned upon your continued compliance with your obligations under Section 4 below and your execution
and delivery to the Company of an effective Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing payments
and benefits upon termination of your employment shall constitute the exclusive severance payments and benefits due to you upon
a termination of your employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon your termination
of employment with the Company for any reason, you will be deemed to have resigned, as of the Termination Date, from all positions
you then hold with the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the termination
of your employment with the Company for any reason, you will reasonably cooperate with the Company upon reasonable request of the
CEO or the Board or and be reasonably available to the Company (taking into account your other business endeavors) with respect
to matters arising out of your services to the Company and its subsidiaries, including, in connection with any legal proceeding,
providing testimony and affidavits; <U>provided</U>, <U>that</U>, the Company shall make reasonable efforts to minimize disruption
of your other activities. The Company shall reimburse you for reasonable expenses incurred in connection with such cooperation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this
offer letter, the following terms have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Cause</U>&rdquo;
shall mean: (a) your substantial failure to perform your duties (other than any such failure resulting from incapacity due to physical
or mental disability) that continues for fifteen (15) calendar days after written notice from the Company; (b) your failure to
comply with any valid and legal directive of the CEO or the Board (as applicable) that continues for fifteen (15) calendar days
after written notice from the Company; (c) your engagement in dishonesty, illegal conduct, or misconduct (or the discovery of your
having engaged in such conduct), which, in each case, materially harms or is reasonably likely to materially harm the Company or
its subsidiaries; (d) your embezzlement, misappropriation, or fraud, whether or not related to your employment with the Company;
(e) your conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony; (f) your willful violation of
a material policy of the Company; (g) your willful or grossly negligent unauthorized disclosure of Confidential Information (as
defined below); or (h) your material breach of any material obligation under this offer letter or any other written agreement between
you and the Company that continues for fifteen (15) calendar days after written notice from the Company (if such breach is reasonably
curable); or (i) any willful material failure by you to comply with the Company&rsquo;s written policies or written rules, as they
may be in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Change
in Control</U>&rdquo; shall have the meaning defined in subparagraph (ii) of the definition of such term under the Appendix in
the Plan as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Disability</U>&rdquo;
shall occur, subject to applicable law, when you are entitled to receive long-term disability benefits under the Company&rsquo;s
long-term disability plan, or if there is no such plan, your inability, due to physical or mental incapacity, to perform the essential
functions of your job for one hundred eighty (180) calendar days out of any three hundred sixty-five (365) day period or one hundred
twenty (120) consecutive calendar days. Any question as to the existence of your Disability as to which you and the Company cannot
agree shall be determined in writing by a qualified independent physician mutually acceptable to you and the Company. If you and
the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians
shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company
and you shall be final and conclusive for all purposes of this offer letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Good
Reason</U>&rdquo; shall mean the occurrence of any of the following, in each case without your written consent: (a) a material
reduction of at least ten percent (10%) of your Base Salary other than a general reduction in Base Salary that affects all similarly
situated executives in substantially the same position; (b) a material reduction of at least thirty percent (30%) of the Target
Annual Bonus Opportunity other than a general reduction in the Target Annual Bonus Opportunity that affects all similarly situated
executives in substantially the same position; (c) a permanent relocation of your principal place of employment by more than thirty-five
(35) miles; (d) any material breach by the Company of any material provision of this offer letter; or (e) a material adverse change
in your title, authority, duties, or responsibilities (including the reporting structure applicable to you, other than temporarily
while you are physically or mentally incapacitated); <U>provided</U>, <U>however</U>, that you cannot terminate your employment
for Good Reason unless you have provided written notice to the Company of the existence of the circumstances providing grounds
for termination for Good Reason within sixty (60) calendar days following the initial existence of such grounds and the Company
has had thirty (30) calendar days from the date on which such notice is provided to cure such circumstances. If you do not terminate
your employment for Good Reason within sixty (60) calendar days after expiration of the cure period (in which the Company shall
not have so cured such grounds), then you will be deemed to have waived your right to terminate for Good Reason with respect to
such grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify; padding-right: 9.55pt"><U>Restrictive Covenants</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">This offer
of employment is contingent on your signing the Company&rsquo;s standard Employee Confidentiality, Non-competition, Policy on Insider
Trading, Whistle Blower Policy, Code of Ethics, Proprietary Information Agreement, attached hereto as <U>Exhibit A</U>, the terms
of which are incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify; padding-right: 9.55pt"><U>Conditions of Employment</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">This offer
of employment is contingent on you providing an I-9 Employment Verification Form. You will be required to submit documentation
that establishes identity and employment eligibility in accordance with the US Immigration and Naturalization requirements, if
appropriate. The offer of employment contained in this offer letter, and your continued employment, is contingent upon and subject
to a satisfactory background and reference check (which you hereby authorize), including but not limited to a confirmation of your
stated credentials. It will be in the Company&rsquo;s sole discretion at any time to determine the scope of the background and
reference check, whether and when to conduct or update such background check and reference check and whether such check is satisfactory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify; padding-right: 9.35pt"><U>At-Will Employment</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify; text-indent: 0.5in">Your employment
with the Company is at-will. This means that you will have the right to terminate your employment relationship with the Company
at any time for any reason. Similarly, the Company will have the right to terminate its employment relationship with you at any
time for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify; padding-right: 9.55pt"><U>Section 409A</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify; text-indent: 0.5in">To the extent
applicable, it is intended that this offer letter (including all amendments hereto, if any) either meets the requirements for exclusion
from coverage under Section 409A, or alternatively complies with the requirements of Section 409A, so that the income inclusion
provisions of Section 409A(a)(1) of the Code do not apply to you. This offer letter shall be interpreted and administered in a
manner consistent with this intent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify; text-indent: 0.5in">To the extent
that payment of amounts under this offer letter that are subject to Section 409A are payable upon your termination of employment,
such amounts shall only be payable if such termination also constitutes a &quot;separation from service,&quot; within the meaning
of Section 409A, from the Company and its affiliates. If you are deemed on the date of your separation from service to be a &quot;specified
employee&quot; (within the meaning of Section 409A(a)(2)(B) of the Code) of the Company, then, notwithstanding any other provision
herein, with regard to any payment that is &quot;nonqualified deferred compensation&quot; subject to Section 409A and that is payable
on account of your &quot;separation from service,&quot; such payment shall not be made prior to the earlier of (i) the expiration
of six (6) months following the date of your separation from service, and (ii) the date of your death, following which all payments
so delayed shall be paid to you in a lump sum without interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify; text-indent: 0.5in">Any taxable
reimbursement of business or other expenses provided for under this offer letter that is subject to Section 409A shall be subject
to the following conditions: (i) the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible
for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end
of the year after the year in which such expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation
or exchange for another benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">In applying
Section 409A to amounts paid pursuant to this offer letter, each payment shall be treated as a separate payment and any right to
a series of installment payments under this offer letter shall be treated as a right to a series of separate payments. Whenever
a payment under this offer letter specifies a payment period within a specified number of days, the actual date of payment within
the specified period shall be within the sole discretion of the Company. If the consideration and revocation period for the Release
spans two taxable years and any amount hereunder is &ldquo;nonqualified deferred compensation&quot; subject to Section 409A and
payable on account of your separation from service, such payment shall not be made or commence until the second taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify; padding-right: 9.55pt"><U>Section 280G</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">In the event
of a change in ownership or control under Section 280G of the Code, if it shall be determined that any payment or distribution
in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to or for your benefit, whether paid or payable
or distributed or distributable pursuant to the terms of this offer letter or otherwise (a &ldquo;<U>Payment</U>&rdquo;), would
constitute an &ldquo;excess parachute payment&rdquo; within the meaning of Section 280G of the Code, the aggregate present value
of the Payments under this offer letter shall be reduced (but not below zero) to the Reduced Amount (defined below) if and only
if the Accounting Firm (described below) determines that the reduction will provide you with a greater net after-tax benefit than
would no reduction. No reduction shall be made unless the reduction would provide you with a greater net after-tax benefit. The
determinations under this Section 8 shall be made as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 30.25pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
&ldquo;<U>Reduced Amount</U>&rdquo; shall be an amount expressed in present value which maximizes the aggregate present value of
Payments under this offer letter without causing any Payment under this offer letter to be subject to the Excise Tax (defined below),
determined in accordance with Section 280G(d)(4) of the Code. The term &ldquo;<U>Excise Tax</U>&rdquo; means the excise tax imposed
under Section 4999 of the Code, together with any interest or penalties imposed with respect to such excise tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 30.25pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
under this offer letter shall be reduced on a nondiscretionary basis in such a way as to minimize the reduction in the economic
value deliverable to you. Where more than one payment has the same value for this purpose and they are payable at different times,
they will be reduced on a pro-rata basis. Only amounts payable under the offer letter shall be reduced pursuant to this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 30.25pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
determinations to be made under this Section shall be made by an independent certified public accounting firm selected by the Company
and agreed to by you immediately prior to the change in ownership or control transaction (the &ldquo;<U>Accounting Firm</U>&rdquo;).
The Accounting Firm shall provide its determinations and any supporting calculations both to the Company and you within ten (10)
days of the transaction. Any such determination by the Accounting Firm shall be binding upon the Company and you. All of the fees
and expenses of the Accounting Firm in performing the determinations referred to in this Section shall be borne solely by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify; padding-right: 9.55pt"><U>Miscellaneous</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">All amounts
paid to you under this offer letter during or following your employment shall be subject to withholding and other employment taxes
imposed by applicable law, and the Company shall withhold from any payments under this offer letter all federal, state and local
taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. You shall be solely responsible
for the payment of all taxes imposed on you relating to the payment or provision of any amounts or benefits hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">This offer
letter may be executed by .pdf or facsimile signatures in any number of counterparts, each of which shall be deemed an original,
but all such counterparts shall together constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">From and
after the Effective Date, this offer letter (including <U>Exhibit A</U> hereto) constitutes the entire agreement between you and
the Company, and supersedes all prior representations, agreements and understandings (including any prior course of dealings),
both written and oral, between you and the Company with respect to the subject matter hereof. In the event of any inconsistency
between this offer letter and any other plan, program, practice or agreement in which you are a participant or a party, this offer
letter shall control unless such other plan, program, practice or agreement is more favorable to you (term by term) or specifically
refers to this offer letter as not controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">This offer
letter and any of the provisions hereof may be amended, waived (either generally or in a particular instance and either retroactively
or prospectively), modified or supplemented, in whole or in part, only by written agreement signed by you and the Company. This
offer letter and your rights and obligations hereunder, may not be assigned by you, and any purported assignment by you in violation
hereof shall be null and void. The Company is authorized to assign this offer letter to a successor to substantially all of its
assets or business. Nothing in this offer letter shall confer upon any person not a party hereof, or the legal representatives
of such person, any rights or remedies of any nature or kind whatsoever under or by reason of this offer letter, except the personal
representative of the deceased. This offer letter shall inure to the benefit of, and be binding on, the successors and assigns
of each of the parties, including, without limitation, your heirs and the personal representatives of your estate and any successor
to all or substantially all of the business and/or assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">No remedy
conferred upon a party by this offer letter is intended to be exclusive of any other remedy, and each and every such remedy shall
be cumulative and shall be in addition to any other remedy given under this offer letter or now or hereafter existing at law or
in equity. Except as explicitly provided herein, no delay or omission by a party in exercising any right, remedy or power under
this offer letter or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may
be exercised by such party from time to time and as often as may be deemed expedient or necessary by such party in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">This offer
letter shall be construed and enforced in accordance with, and the laws of the State of New York, without giving effect to the
conflicts of law principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">Any reference
to a Section of the Code shall be deemed to include any successor to such Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This offer letter and the compensation payable
hereunder shall be subject to any applicable clawback or recoupment policies, share trading policies, and other policies that may
be implemented by the Board from time to time with respect to officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any notices required or permitted hereunder
or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when hand delivered
or mailed by registered or certified mail, if to the Company, to the CEO at the address above, and if to you at the most recent
address in the Company&rsquo;s records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">Please acknowledge
your acceptance of this offer by returning a signed copy of this offer letter. If there are any other agreements of any type that
you are aware of that may impact or limit your ability to perform your job at the Company, please let us know as soon as possible.
In accepting this offer, you represent and warrant to the Company that you are not subject to any legal or contractual restrictions
that would in any way impair your ability to perform your duties and responsibilities to the Company, and that all information
you provided to the Company is accurate and complete in all respects. This offer will remain open until October 4, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">Formalities
aside, we are very excited about having you join our team. Your skills and experiences are a great match with our goals, and I
anticipate you being a critical part of the Company&rsquo;s success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0in"><U>/s/ Carsten Thiel, Ph.D.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Carsten Thiel, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Chief Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><I>Abeona Therapeutics
Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 0; text-align: justify; text-indent: 0in">I accept this
offer of employment with Abeona Therapeutics and will begin employment on October 24, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 35%">Signature:</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">Date:</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Jo&atilde;o Siffert, M.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">4 - Oct - 2018</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: center"><B>EMPLOYEE CONFIDENTIALITY, NON-COMPETITION,
AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: center"><B>PROPRIETARY INFORMATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">THIS AGREEMENT, effective as of <B>24 October,
2018</B> between Abeona Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and <B>Joao Siffert, MD</B>
(the &ldquo;<U>Employee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee will make full and prompt disclosure to the Company of all inventions, improvements, modifications, discoveries,
methods, technologies, biological materials, and developments, and all other materials, items, techniques, and ideas related directly
or indirectly to the business of the Company (collectively, &ldquo;<U>Intellectual Property</U>&rdquo;), whether patentable or
not, made or conceived by Employee or under Employee&rsquo;s direction during Employee&rsquo;s employment with the Company, whether
or not made or conceived during normal working hours, or on the premises of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee agrees that all Intellectual Property, as defined above, shall be the sole property of the Company and its assigns,
and the Company and its assigns shall be the sole owner of all patents and other rights in connection therewith. Employee hereby
assigns to the Company any rights Employee may have or acquire in all Intellectual Property and all related patents, copyrights,
trademarks, trade names, and other industrial and intellectual property rights and applications therefore, in the United States
and elsewhere. Employee further agrees that with regard to all future developments of Intellectual Property, Employee will assist
the Company in every way that may be reasonably required by the Company (and at the Company&rsquo;s expense) to obtain and, from
time to time, enforce patents on Intellectual Property in any and all countries that the Company may require, and to that end,
Employee will execute all documents for use in applying for and obtaining such patents thereon and enforcing the same, as the Company
may desire, together with any assignment thereof to the Company or persons designated by the Company, and Employee hereby appoints
the Company as Employee&rsquo;s attorney to execute and deliver any such documents or assignments requested by the Company. Employee&rsquo;s
obligation to assist the Company in obtaining and enforcing patents for Intellectual Property in any and all countries shall continue
beyond the termination of Employee&rsquo;s employment with the Company, but the Company shall compensate Employee at a reasonable,
standard hourly rate following such termination for time directly spent by Employee at the Company&rsquo;s request for such assistance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee hereby represents that Employee has no continuing obligation to assign to any former employer or any other person,
corporation, institution, or firm any Intellectual Property as described above. Employee represents that Employee&rsquo;s performance
of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence
proprietary information acquired by Employee, in confidence or in trust, prior to Employee&rsquo;s employment by the Company. Employee
has not entered into, and Employee agrees not to enter into, any agreement (either written or oral), which would put Employee in
conflict with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee agrees to assign to the Company any and all copyrights and reproduction rights to any material prepared by Employee
in connection with this Agreement and/or developed during the term of Employee&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee understands and agrees that a condition of Employee&rsquo;s employment and continued employment with the Company
is that Employee has not brought and will not bring to the Company or use in the performance of Employee&rsquo;s duties at the
Company any materials or documents rightfully belonging to a former employer which are not generally available to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.35pt 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee recognizes that the services to be performed by Employee hereunder are special, unique, and extraordinary and that,
by reason of Employee&rsquo;s employment with the Company, Employee may acquire Confidential Information (as hereinafter defined)
concerning the operation of the Company, the use or disclosure of which would cause the Company substantial loss and damage which
could not be readily calculated and for which no remedy at law would be adequate. Accordingly, except as provided in the last Paragraph
in this Section 6, Employee agrees that Employee will not (directly or indirectly) at any time, whether during or after Employee&rsquo;s
employment with the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.35pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.75pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify; padding-right: 5.25pt">knowingly use for personal benefit or for any other reason not authorized
by the Company any Confidential Information that Employee may acquire or has acquired by reason of Employee&rsquo;s employment
with the Company, or;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 77.75pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.75pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify; padding-right: 5.35pt">disclose any such Confidential Information to any person or entity except
(A) in the performance of Employee obligations to the Company hereunder, (B) as required by a court of competent jurisdiction,
or (C) with the prior consent of the Board of Directors of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.35pt 0pt 77.75pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.15pt 0pt 0; text-align: justify; text-indent: 0.5in">As used
herein, &ldquo;<U>Confidential Information</U>&rdquo; includes information with respect to the facilities and methods of the Company,
reagents, chemical compounds, cell lines or subcellular constituents, organisms, or other biological materials, trade secrets,
and other Intellectual Property, systems, patents and patent applications, procedures, manuals, confidential reports, financial
information, business plans, prospects, or opportunities, personnel information, or lists of customers and suppliers; <U>provided</U>,
<U>however</U>, that Confidential Information shall not include any information that is known or becomes generally known or available
publicly other than as a result of disclosure by Employee which is not permitted as described in clause (ii) above, or the Company
discloses same to others without obtaining an agreement of confidentiality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.15pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 0; text-align: justify; text-indent: 0.5in">Employee
confirms that all Confidential Information is the exclusive property of the Company. All business records, papers, documents and
electronic materials kept or made by Employee relating to the business of the Company which comprise Confidential Information shall
be and remain the property of the Company during the Employee&rsquo;s employment and at all times thereafter. Upon the termination,
for any reason, of Employee&rsquo;s employment with the Company, or upon the request of the Company at any time, Employee shall
deliver to the Company, and shall retain no copies of any written or electronic materials, records and documents made by Employee
or coming into Employee&rsquo;s possession concerning the business or affairs of the Company and which comprise Confidential Information.
To the extent that, upon termination, Employee has any Confidential Information or other proprietary material of the Company stored
within any PDA or personal computer, email account, thumb drive or other storage device or cloud storage, Employee agrees to fully
cooperate with the Company to return such information and material and subsequently permanently delete and remove such information
and material from such devices (subject to any litigation preservation directive in effect), including, as necessary, providing
access by the Company to such devices to ensure compliance with this Paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in
this Agreement shall prohibit or restrict Employee from lawfully (a) initiating communications directly with, cooperating with,
providing information to, causing information to be provided to, or otherwise assisting in an investigation by any governmental
or regulatory agency, entity, or officials, including the Food and Drug Administration, the Securities and Exchange Commission
and the Equal Employment Opportunity Commission (collectively, &ldquo;<U>Governmental Authorities</U>&rdquo;) regarding a possible
violation of any law; (b)&nbsp;responding to any inquiry or legal process directed to Employee individually (and not directed to
the Company) from any such Governmental Authorities; (c) testifying, participating or otherwise assisting in an action or proceeding
by any such Governmental Authorities relating to a possible violation of law; or (d) making any other disclosures that are protected
under the whistleblower provisions of any applicable law. Notwithstanding the foregoing, Employee agrees that in making any such
disclosures or communications, Employee will take all reasonable precautions to prevent any unauthorized use or disclosure of any
information that may constitute Company Confidential Information to any parties other than any Governmental Authority. Employee
further understands that Employee is not permitted to disclose the Company&rsquo;s attorney-client privileged communications or
attorney work product unless required by applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016,
Employee shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade
secret that: (i) is made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or
to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made to Employee&rsquo;s
attorney in relation to a lawsuit for retaliation against Employee for reporting a suspected violation of law; or (iii) is made
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Nor does this Agreement
require Employee to obtain prior authorization from the Company before engaging in any conduct described in this Paragraph, or
to notify the Company that you have engaged in any such conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During the term of Employee&rsquo;s employment with the Company and for one (1) year thereafter (the &ldquo;<U>Restricted
Period</U>&rdquo;), the Employee shall not directly or indirectly, for Employee&rsquo;s own account or for the account of others,
as an officer, director, stockholder (other than as the holder of less than 1% of the outstanding stock of any publicly traded
company), owner, partner, employee, promoter, investor, consultant, manager or otherwise participate in the promotion, financing,
ownership, operation, or management of, or assist in or carry on through proprietorship, a corporation, partnership, or other form
of business entity which is in competition with the Company in the field of RNA interference (RNAi) (the &ldquo;<U>Company Business</U>&rdquo;)
within the United States or any other country in which the Company is conducting or is actively seeking or planning to conduct
the Company Business as of the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">During the
Restricted Period, the Employee shall not, whether for Employee&rsquo;s own account or for the account of any other person (excluding
the Company): (i) solicit or contact in an effort to do business with any person who was or is a customer or prospective customer
(i.e., any individual or entity with whom the Company was actively engaged in soliciting to do business) of the Company, or any
affiliate of the Company, at the time of Employee&rsquo;s termination or at any time during the two (2) year period prior to Employee&rsquo;s
termination, if such solicitation or contact is for the purpose of competition with the Company; or (ii) solicit or induce any
of the Company&rsquo;s employees to leave their employment with the Company or accept employment with anyone else, or hire any
such employees or persons who were employed by the Company during the preceding twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">Nothing herein
shall prohibit or preclude the Employee from performing any other types of services that are not precluded by this Section 7 for
any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">Employee
has carefully read and considered the provisions of this Section 7 (including the Restricted Period, scope of activity to be restrained,
and the restriction&rsquo;s geographical scope) and concluded them to be fair, appropriate and reasonably required for the protection
of the legitimate business interests of the Company, its officers, directors, employees, creditors, and shareholders. Employee
understands that the restrictions contained in this Section 7 may limit Employee&rsquo;s ability to engage in a business similar
to the Company&rsquo;s business, but acknowledges that Employee will receive adequate and affluent remuneration and other benefits
from the Company hereunder to justify such restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">The Employee
shall give prompt notice to the Company of the Employee&rsquo;s acceptance of employment or other fees for services relationship
during the Restricted Period, which notice shall include the name of, the business of, and the position that Employee shall hold
with such other employer. Employee also agrees to inform any prospective employer or business entity or person of the restrictions
set forth in this Agreement prior to accepting employment or entering into any business relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that Employee&rsquo;s employment is transferred by the Company to a subsidiary, affiliated company, or acquiring
company (as the case may be), Employee&rsquo;s employment by such company will, for the purpose of this Agreement, be considered
as continued employment with the Company, unless Employee executes an agreement, substantially similar in substance to this Agreement,
and until the effective date of said agreement in any such company for which Employee becomes employed. It is likewise agreed that
no changes in Employee&rsquo;s position or title will operate to terminate the provisions of this Agreement unless expressly agreed
to in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon termination of Employee&rsquo;s employment for any reason, unless such employment is transferred to a subsidiary, affiliated
or acquiring company of the Company, Employee agrees to leave with, or return to, the Company all records, drawings, notebooks,
and other documents pertaining to the Company&rsquo;s Confidential Information, whether prepared by Employee or others, as well
as any equipment, tools or other devices owned by the Company, that are then in Employee&rsquo;s possession, however such items
were obtained, and Employee agrees not to reproduce or otherwise retain any document or data relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to Section 6 with respect to disclosure to Governmental Authorities, Employee agrees and covenants that he will
not at any time make, publish or communicate to any person or entity or in any public forum any defamatory or disparaging remarks,
comments, or statements concerning the Company or its businesses, or any of its employees, officers, and existing and prospective
customers, suppliers, investors and other associated third parties. The Company agrees and covenants that it will instruct its
Board members and executive officers to not at any time make, publish or communicate to any person or entity or in any public forum
any defamatory or disparaging remarks, comments, or statements concerning Employee or his or her business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee&rsquo;s obligations under this Agreement shall survive the termination of Employee&rsquo;s employment with the
Company regardless of the manner of, and reason for, such termination or resignation, and shall be binding upon Employee&rsquo;s
heirs, executors, and administrators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Prior to entering the employ of the Company, Employee has lawfully terminated employment with all previous employers. Employee
acknowledges that this Agreement does not constitute a contract of employment for a term and does not otherwise imply that the
Company will continue his or her employment for any period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee agrees that there is no Intellectual Property relevant to the subject matter of Employee&rsquo;s employment with
the Company, which has been made or conceived or first reduced to practice by Employee alone or jointly with others prior to Employee&rsquo;s
employment with the Company, which Employee desires to exclude from Employee&rsquo;s obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any
other right. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed
as a bar to or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee agrees that in addition to any other rights and remedies available to the Company for any breach or threatened
breach by Employee of Employee&rsquo;s obligations hereunder, the Company shall be entitled to enforcement of Employee&rsquo;s
obligations hereunder by whatever means are at the Company&rsquo;s disposal, including court injunction, without having to post
a bond or other security. In the event of any such breach or threatened breach by Employee, the Company shall be entitled to recover
all of its reasonably incurred costs and attorney&rsquo;s fees in enforcing its rights hereunder, and the Restricted Period shall
be extended by the period of any such breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company may assign this Agreement to any other corporation or entity which acquires (whether by purchase, merger, consolidation
or otherwise) all or substantially all of the business and/or assets of the Company. Employee shall have no rights of assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If any provision of this Agreement shall be declared invalid, illegal, or unenforceable, then such provision shall be enforceable
to the extent that a court deems it reasonable to enforce such provision. If such provision shall be unreasonable to enforce to
any extent, such provision shall be severed and all remaining provisions shall continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employee hereby acknowledges receipt of the Company&rsquo;s Confidentiality Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement shall be effective as of the date set forth below next to Employee&rsquo;s signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement and the employment offer letter constitute the entire contract between the parties hereto with regard to
the subject matter hereof. They supersede any other agreements, representations or understandings (whether oral or written and
whether express or implied) which relate to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify; text-indent: 0.5in">21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement shall be governed in all respects by the laws of the State of New York. Each of the Company and Employee
(a) hereby irrevocably submits to the exclusive jurisdiction of the state courts of the State of New York or the United States
District Court located in New York, New York for the purpose of any action between the Company and Employee arising in whole or
in part under or in connection with this Agreement, (b) hereby waives, to the extent not prohibited by applicable law, and agrees
not to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to
the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such action
brought in one of the above-named courts should be dismissed on grounds of forum non conveniens, should be transferred or removed
to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in
any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced
in or by such court, and (c) hereby agrees not to commence any such action other than before one of the above-named courts. Notwithstanding
the previous sentence, the Company or Employee may commence any action in a court other than the above-named courts solely for
the purpose of enforcing an order or judgment issued by one of the above-named courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS
WHEREOF</B>, Employee has executed this Agreement under seal as of the date set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 293.75pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70%; text-indent: 0in">EMPLOYEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70%; text-indent: 0in">By:&nbsp;<U>&nbsp;&nbsp;/s/ Joao Siffert, MD&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70%; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70%; text-indent: 0in">Name: Joao Siffert, MD</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ACCEPTED AND AGREED TO BY THE COMPANY:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 248.9pt 0pt 0; text-indent: 0in">By: <U>/s/ Carsten Thiel, Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 248.9pt 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 248.9pt 0pt 0; text-indent: 0in">Name: Carsten Thiel, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 248.9pt 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 248.9pt 0pt 0; text-indent: 0in">Title: Chief Executive Officer</P>



<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tv507897_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><P STYLE="margin: 0pt 0">November
29, 2018</P>


</TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: right"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 91px; width: 264px"></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Joao Siffert, MD</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">155 E 72<SUP>nd</SUP> Street, #13D</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10021</P>
</TD>
    <TD STYLE="text-align: left"></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Joao,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This letter agreement (the &ldquo;Letter Agreement&rdquo;) confirms
the recent agreement between you and Abeona Therapeutics Inc. (the &ldquo;Company&rdquo;) regarding your appointment as Interim
Chief Executive Officer and the increase in your base salary while you are serving in that role. This Letter Agreement shall be
effective for the period commencing on November 26, 2018 and ending on the earlier of (i) such date that you cease to serve as
the Interim Chief Executive Officer for any reason or (ii) May 26, 2019 (the &ldquo;Term&rdquo;). If it is determined by you and
the Company that you will remain the Interim Chief Executive Officer beyond the period specified in this Letter Agreement, the
terms of such continued appointment shall be further agreed to and memorialized in an amendment hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You and the Company have agreed that during the Term solely
for purposes of the first sentence of Section 2 of the Offer Letter between you and the Company, dated September 28, 2018 (the
&ldquo;Offer Letter&rdquo;), your Base Salary (as defined in the Offer Letter), shall be increased from $450,000 to $550,000 (the
&ldquo;Salary Increase&rdquo;). Notwithstanding the Salary Increase, for purposes of the remainder of the Offer Letter, including
Section 2 with respect to the calculation of the Target Annual Bonus Opportunity (as defined in the Offer Letter), and Section
3 with respect to the calculation of severance and the definition of Good Reason, your &ldquo;Base Salary&rdquo; shall continue
to be considered $450,000. Except to the extent modified by this Letter Agreement, the terms of the Offer Letter shall otherwise
remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Letter Agreement does not confer upon you any right to
continue in service with the Company or otherwise interfere with the right of the Company to terminate your service at any time
for any reason. This Letter Agreement will be construed in accordance with, and governed by, the laws of the State of New York.
This Letter Agreement may only be changed by an agreement in writing signed by you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you for your commitment to the Company during this transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Steven H. Rouhandeh</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven H. Rouhandeh</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Chairman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AGREED TO AND ACCEPTED:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">/s/ Joao Siffert, MD</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 45%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Joao Siffert, MD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date: November 29, 2018</TD></TR>
</TABLE>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>tv507897_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">November 26, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">F. Carsten Thiel, PhD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14 Charcoal Hill Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Westport, CT 06880</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Re: Confidential Separation and General
Release Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Carsten:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Confidential Separation
and General Release Agreement (the &ldquo;<U>Agreement</U>&rdquo; or &ldquo;<U>Separation Agreement</U>&rdquo;) confirms our mutual
agreement regarding the terms and conditions of your separation from employment with Abeona Therapeutics Inc. (the &ldquo;<U>Company</U>&rdquo;).
You and the Company (each referred to herein individually as a &ldquo;Party&rdquo; and together as the &ldquo;Parties&rdquo;) agree
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD STYLE="text-align: justify"><B><U>Employment</U>.</B> Your last day of employment with the Company will be November 26, 2018
(&ldquo;<U>Last Day of Employment</U>&rdquo;). You will continue to receive your regular benefits and salary at your regular rate
of pay through your Last Day of Employment. Thereafter, you may elect to continue coverage under certain Company health plans through
the Consolidated Omnibus Budget Reconciliation Act (&ldquo;COBRA&rdquo;). If you timely and properly elect COBRA continuation coverage,
provided you timely submit documentation of your monthly COBRA payment to the Company, you shall be reimbursed for the cost of
COBRA coverage for six (6) months or until you obtain health benefits through new employment, whichever is sooner. In the event
you secure new employment prior to the end of the six (6) month period, you agree that you will notify the Company for the purpose
of terminating your COBRA reimbursement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD STYLE="text-align: justify"><B><U>Consideration</U>. </B>In consideration for your release of claims set forth in Paragraph
3 hereof, to the maximum extent permitted by law, the Company hereby waives, releases and forever discharges you from any and all
claims against you legally capable of being waived and currently known to the Company, based upon or arising from any fact or set
of facts up until the date of execution of this Agreement, arising out of or relating in any way to any allegations made against
you during your employment with the Company; provided, however, that the Company does not hereby waive any right it has under this
Agreement or any claim arising after execution of this Agreement, and further does not waive any act or omission by you constituting:
(i) fraud or a crime; or (ii) a violation of regulations applicable to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>3.</B></TD><TD STYLE="text-align: justify"><B><U>Release</U>. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">In exchange for the consideration set forth in Paragraph 2 hereof, to the maximum extent permitted
by law, you hereby waive, release and forever discharge the Company and each of its past, present and future parents, subsidiaries,
and affiliates, and each of its and their respective past, present and future directors, officers, members, managers and employees
in their personal and professional capacities, contractors, equityholders, trustees, representatives, agents, advisors, employee
benefit plans (and such plans&rsquo; administrators, fiduciaries, trustees, recordkeepers and service providers), successors (through
acquisition, merger or otherwise) and permitted assigns, each and all of them in their personal and representative capacities (collectively
the &ldquo;<U>Company Releasees</U>&rdquo;), from any and all claims legally capable of being waived, grievances, injuries, torts
or unlawful conduct of any kind, controversies, agreements, covenants, promises, debts, accounts, actions, causes of action, suits,
arbitrations, sums of money, attorneys&rsquo; fees, costs, damages, or any right to any monetary recovery or any other personal
relief, whether known or unknown, in law or in equity, which you now have, have ever had, or may hereafter have, based upon or
arising from any fact or set of facts, whether known or unknown to you, arising at any time prior to the date you execute this
Agreement including, without limitation, claims arising out of or relating in any way to your employment with the Company or any
of the other Company Releasees, or other associations with the Company or any of the other Company Releasees, or any termination
thereof, or any allegations made against you during your employment with the Company. Without limiting the generality of the foregoing,
this waiver, release, and discharge includes any claim or right, to the maximum extent legally capable of being waived, based upon
or arising under any federal, state or local fair employment practices or equal opportunity laws, including, but not limited to,
42 U.S.C. Section 1981, Title VII of the Civil Rights Act of 1964, the Equal Pay Act, the Employee Retirement Income Security Act
(&ldquo;<U>ERISA</U>&rdquo;) (including, but not limited to, claims for breach of fiduciary duty under ERISA), the Americans With
Disabilities Act, the Family and Medical Leave Act of 1993, the New York State Executive Law, including its Human Rights Law, the
New York City Administrative Code, including its Human Rights Law, the New York Labor Law, and the New York State Constitution,
including all amendments thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver
by you of, or prevents you from making or asserting (i) any claim or right you may have under COBRA; (ii) any claim to vested benefits
under the written terms of a qualified employee pension benefit plan; (iii) any claim for indemnity under applicable Company bylaws
or policies; or (iv) any claim or right you may have under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>4.</B></TD><TD STYLE="text-align: justify"><B><U>No Entitlement to Future Employment</U>.</B> You acknowledge and agree that this Agreement
waives and releases any entitlement you may have to apply for or seek future employment with the Company or any other Company Releasee.
Accordingly, you agree that you will not apply for or seek future employment with the Company or any other Company Releasee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>5.</B></TD><TD><B><U>Cooperation</U>.</B> To the maximum extent permitted by law and subject to Paragraph 8(c)(i)-(iii), you agree to reasonably
cooperate with and assist the Company in connection with any investigation, regulatory matter, lawsuit or arbitration in which
the Company is a subject, target or party and as to which you may have pertinent information. You agree that you shall make yourself
reasonably available for preparation for hearings, proceedings or litigation and for attendance at any pre-trial discovery and
trial sessions. You further agree to perform all acts and to execute any and all documents that may reasonably be necessary to
carry out the provisions of this Paragraph 5.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>6.</B></TD><TD STYLE="text-align: justify"><B><U>Return of Property/Materials</U>.</B> By November 30, 2018, you agree to promptly return
to the Company all of its property, including, but not limited to, computers, PDAs, cell phones, files, documents, identification
cards, credit cards, keys, equipment, software and data, however stored. You further agree to permanently delete all Company information
and material from any personal email, PDA or other computer or storage device. You further agree that prior to executing this Agreement
you have conducted a diligent search for any communications, emails, documents, texts, messages videos, photos or other material
related to the Company and/or any allegations made against you while employed by the Company and that you have provided those materials
to the Company General Counsel, Neena Patil via electronic mail, hand delivery or Federal Express pursuant to Paragraph 14(f),
and you further represent and warrant that you have permanently deleted all such communications, emails, documents, texts, messages,
videos, photos and other material related to the Company from all personal PDAs, computers, email accounts, cloud storage and/or
other devices or mediums. You agree that, if you discover or receive any Company property or materials related to the Claims after
signing this Agreement, you will return it to the Company or the Company General Counsel, Neena Patil within 48 hours of discovery
or receipt. You further agree that any breach of this provision shall constitute a material breach of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>7.</B></TD><TD STYLE="text-align: justify"><B><U>No Additional Entitlements.</U></B> You agree that, other than as provided for in this Agreement
you have received all entitlements due from the Company relating to your employment with the Company, including, but not limited
to, all wages earned, sick pay, vacation pay, overtime pay, and any paid and unpaid personal leave for which you were eligible
and entitled, and that no other entitlements are due to you other than as set forth in this Agreement. You expressly agree that
you waive, and have no entitlement to any severance, bonus or other compensation under your employment agreement with the Company
dated March 29, 2018 (the &ldquo;Employment Agreement&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>8.</B></TD><TD STYLE="text-align: justify"><B><U>Confidentiality/Non-Disparagement/Non-Publication</U>. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify"><U>Continuing Obligations</U>. Subject to Paragraph 8(c)(i)-(iii), you hereby acknowledge the existing
obligations, and the legal enforceability of such obligations, contained in (i) the Employment Agreement, including, without limitation,
paragraph 4 (&ldquo;Unauthorized Disclosure; Non-Competition; Non-Solicitation; Interference with Business Relationships; Proprietary
Rights&rdquo;) including each of its subparts, and paragraph 6 (&ldquo;Non-Disparagement&rdquo;); and (ii) any agreements you have
entered into during your employment with the Company requiring you to maintain confidentiality. You agree to be bound by the agreements
in Paragraph 8(a)(i) &ndash; (ii) and acknowledge that their terms and conditions remain in full force and effect. Notwithstanding
the foregoing, provided that you comply with your obligations herein, the Restriction Period, as defined in the Employment Agreement,
shall be reduced to six (6) months with respect to your non-competition obligations only, as set forth in paragraph 4.3 of the
Employment Agreement. The Restriction Period shall remain one (1) year with respect to all other applicable provisions in the Employment
Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify"><U>Agreement Not to Disparage</U>. Subject to Paragraph 8(c)(i)-(iii), you further agree that,
in addition to your obligations contained in Paragraph 8(a) hereof, you shall not, directly or indirectly, at any time make, publish
or communicate, or cause, direct, induce, or encourage any other person, entity or other third party to make, publish or communicate,
whether anonymously or not, any statement, observation, opinion or information, whether verbal or written, of a defamatory or disparaging
nature regarding, or that is likely in any way to harm the reputation of, embarrass, humiliate or otherwise cause or contribute
to their being held in disrepute, the Company or any other Company Releasee, the business or products of the Company or any other
Company Releasee, or any of the Company&rsquo;s or any other Company Releasee&rsquo;s respective employees, officers, directors,
contractors, equityholders, members, agents, representatives, agents, advisors, successors or permitted assigns. Subject to Paragraph
8(c)(i)-(iii), the Company agrees to instruct its Board of Directors and executive officers not to publish or communicate any statement
of a defamatory or disparaging nature regarding you.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify"><U>Permitted Conduct; DTSA</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">Nothing in this Agreement shall prohibit or restrict
you from lawfully (a) initiating communications directly with, cooperating with, providing information to, causing information
to be provided to, or otherwise assisting in an investigation by any governmental or regulatory agency, entity, or official(s)
(collectively, &ldquo;<U>Governmental Authorities</U>&rdquo;) regarding a possible violation of any law; (b) responding to any
inquiry or legal process directed to you individually (and not directed to Company or any of its affiliates) from any such Governmental
Authorities; (c) testifying, participating or otherwise assisting in an action or proceeding by any such Governmental Authorities
relating to a possible violation of law; or (d) making any other disclosures that are protected under the whistleblower provisions
of any applicable law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">ii.</TD><TD STYLE="text-align: justify">Pursuant to the federal Defend Trade Secrets Act of 2016, you shall not be held criminally or civilly
liable under any federal or state trade secret law for the disclosure of a trade secret that is made (i)(1) in confidence to a
federal, state, or local government official, either directly or indirectly, or to an attorney, and (2) solely for the purpose
of reporting or investigating a suspected violation of law; (ii) to your attorney in relation to a lawsuit for retaliation against
you for reporting a suspected violation of law; or (iii) in a complaint or other document filed in a lawsuit or other proceeding,
if such filing is made under seal.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">iii.</TD><TD STYLE="text-align: justify">Furthermore, this Agreement does not require you to obtain prior authorization from the Company
before engaging in any conduct described in Paragraph 8(c)(i)-(ii), or to notify the Company that you have engaged in any such
conduct.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>9.</B></TD><TD STYLE="text-align: justify"><B><U>Additional Acknowledgement</U>.</B> You acknowledge and agree that you are not aware of any
facts or circumstances that you believe may constitute a violation of the Company&rsquo;s or Company Releasees&rsquo; legal obligations
under the Sarbanes-Oxley Act, the False Claims Act, or similar law and/or the whistleblower provisions of any state or federal
law or regulation. You further represent that you have no knowledge of any violation by the Company of any law or regulation applicable
to the Company or its business.&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>10.</B></TD><TD STYLE="text-align: justify"><B><U>Non-Admission</U>.</B> It is understood and agreed that neither the execution of this Agreement,
nor the terms of this Agreement, constitute an admission of liability to you, or of any wrongdoing or misconduct of any kind, by
the Company or any other Company Releasee, and such liability, wrongdoing or misconduct is expressly denied. It is further understood
and agreed that no person shall use this Agreement, or the consideration paid pursuant thereto, as evidence of an admission of
liability, wrongdoing or misconduct of any kind, inasmuch as such liability, wrongdoing or misconduct is expressly denied.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>11.</B></TD><TD STYLE="text-align: justify"><B><U>Acknowledgments</U>.</B> You hereby acknowledge that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">the Company advises you to consult with an attorney before signing this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">you have obtained independent legal advice from an attorney of your own choice with respect to
this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">you freely, voluntarily and knowingly entered into this Agreement after due consideration;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">you have had a reasonable period of time to review and consider this Agreement; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">no promise or inducement has been offered to you, except as expressly set forth herein or contemplated
hereby, and you are not relying upon any such promise or inducement in entering into this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>12.</B></TD><TD STYLE="text-align: justify"><B><U>Revocation by the Company</U>.</B> If you fail to execute and return this Agreement to the
Company by November 30, 2018, the promises and agreements made by the Company herein will be revoked.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>13.</B></TD><TD STYLE="text-align: justify"><B><U>Dispute Resolution</U>. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">The Parties each agree that with respect to any all claims that you or the Company now have or
in the future may have against the other, including, without limitation, contract claims, tort claims, claims for compensation,
penalties or restitution and any other claim under any federal, state or local statute, constitution, regulation, rule, ordinance
or common law, in each case, directly or indirectly arising out of or related to this Agreement, your relationship with the Company,
your employment with the Company or the termination of your employment with the Company (collectively &ldquo;Covered Claims&rdquo;)
the claimant agrees to notify the other Party in writing of any Covered Claim within five (5) days of becoming aware of such Covered
Claim so that the Parties can attempt in good faith to resolve such Covered Claim informally. Such notice must include a detailed
description of the nature or basis of the Covered Claim, and the specific relief sought.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">To the extent that any Covered Claims cannot be resolved pursuant to Paragraph 13(a), and except
with respect to any claim (i) that is expressly precluded from arbitration by a governing federal law or by a state law that is
not preempted by the Federal Arbitration Act, 9 U.S.C. &sect; 1 et seq. (&ldquo;FAA&rdquo;); or (ii) that seeks injunctive or other
equitable relief in aid of arbitration, such Covered Claims are subject to and will be resolved by binding arbitration. The Parties
irrevocably consent and agree that (i) any arbitration will occur in the State of New York; (ii) arbitration will be conducted
confidentially in accordance with the then-current arbitration rules and procedures of the AAA (and its then-existing emergency
relief procedures to the extent either Party seeks emergency relief prior to the appointment of an arbitrator), unless those rules
or procedures conflict with any express term of this Agreement, in which case this Agreement shall control; (iii) the federal courts
sitting in the State of New York, have exclusive jurisdiction over any appeals and the enforcement of an arbitration award; and
(iv) the state or federal courts sitting in the State of New York have exclusive jurisdiction over any claim that is not subject
to arbitration, and in such case, the rights and obligations of the Parties will be governed by, and construed and enforced, both
substantively and procedurally, in accordance with, the laws of the State of New York without regard to choice of law or conflict
of law rules or provisions (whether of the State of New York or any other jurisdiction). Each party shall pay the fees of its attorneys,
the expenses of its witnesses, and any other costs and expenses that the party incurs in connection with the arbitration, but all
other costs of the arbitration, including the fees of the arbitrator, the cost of any record or transcript of the arbitration,
administrative fees, and other fees and costs shall be paid one half by the Company and one half by you. Notwithstanding the foregoing,
the arbitrator may, in his discretion, award reasonable attorneys&rsquo; fees (in addition to any other damages, expenses or relief
awarded) to the prevailing party. EACH PARTY HEREBY IRREVOCABLY CONSENTS AND AGREES TO ARBITRATE ANY COVERED CLAIMS THROUGH BINDING
ARBITRATION, AND FOREVER WAIVES AND GIVES UP ITS RIGHT TO HAVE A JUDGE OR JURY DECIDE ANY COVERED CLAIMS.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>14.</B></TD><TD STYLE="text-align: justify"><B><U>Miscellaneous</U>.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify"><U>Entire Agreement; Amendment</U>. This Agreement, together with the agreements referenced in
Paragraph 8(a), contains the entire agreement, arrangement and understanding of the Parties with respect to the subject matter
hereof, and supersedes and preempts any and all prior or contemporaneous agreements, arrangements or understandings, whether verbal
or written, between the Parties with respect to the subject matter hereof. This Agreement may not be amended, changed or modified
except by an instrument in writing, signed by you and an authorized representative of the Company. The Parties agree that no promise
or inducement has been offered to them, except as expressly set forth herein or contemplated hereby, and the Parties are not relying
upon any such promise or inducement in entering into this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify"><U>Governing Law</U>. This Agreement shall be construed, performed, enforced and in all respects
governed in accordance with the laws of the State of New York, without giving effect to the principles of conflicts of law thereof;
provided, however, that the Parties&rsquo; agreement to arbitrate as set forth in Paragraph 13 hereof, shall be governed by the
Federal Arbitration Act, 9 U.S.C. &sect; 1 <I>et seq</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify"><U>Severability</U>. If any one or more of the terms, provisions, covenants or restrictions contained
in this Agreement shall be determined in an arbitration proceeding conducted pursuant to Paragraph 13 hereof to be invalid, illegal
or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force
and effect and shall in no way be affected, impaired or invalidated and the Parties will attempt to agree upon a valid, legal and
enforceable provision which shall be a reasonable substitute for such invalid and unenforceable provision in light of the tenor
of this Agreement, and, upon so agreeing, shall incorporate such substitute provision in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify"><U>Breach</U>. You acknowledge and agree that if you breach any of your commitments or representations
to the Company in this Agreement, and provided you have received written notice of such breach from the Company and a period of
thirty (30) days following receipt of such notice to cure such breach (if susceptible to cure), the Company may seek any remedy
or damages available to the Company as permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify"><U>No Waiver</U>. A waiver by either Party of a breach of any term or provision of this Agreement
shall not operate or be construed as a continuing waiver or as a consent to or waiver of any subsequent breach hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">f.</TD><TD STYLE="text-align: justify"><U>Notices</U>. All notices, requests, demands and other communications required or permitted hereunder
shall be given in writing and shall be deemed to have been duly given (i) on the date delivered if personally delivered or (ii)
on the date targeted for delivery if delivered by a nationally recognized overnight courier or similar courier service, in each
case, as the case may be, to the Company&rsquo;s or your respective counsel at the addresses set forth below or such other address
as the Company or you may in the future specify in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>If to Abeona Therapeutics Inc.</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Morgan Lewis, &amp; Bockius LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Attention: David McManus, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">101 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">New York, New York 10178-0060</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>If to Dr. Thiel</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Walden Macht &amp; Haran LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Attention: Milton L. Williams Jr.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">One Battery Park Plaza, 33rd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">New York, NY 10004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">g.</TD><TD STYLE="text-align: justify"><U>Public Filing of Agreement</U>. You acknowledge that this Agreement will be publicly filed with
the SEC consistent with the Company&rsquo;s obligations as a public company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">h.</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, and by electronic
signature, each of which shall be deemed to be an original and all of which together will constitute one and the same instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify"><U>Binding Effect; Assignment</U>. This Agreement shall be binding on and inure to the benefit
of each of the Parties and their respective successors and permitted assigns. You may not assign this Agreement, in whole or in
part, or delegate any of your duties or obligations under this Agreement, without the Company&rsquo;s prior written consent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">j.</TD><TD STYLE="text-align: justify"><U>Headings</U>. The Paragraph headings in this Agreement are for the convenience of reference
only and do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">k.</TD><TD STYLE="text-align: justify"><U>Effective Date</U>. This Agreement shall become effective upon your execution and return of
this Agreement to the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>This space intentionally left blank
&ndash; Signature page follows</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the above accurately
states our agreement, including the separation, waiver and release, kindly sign below and return the original Agreement to me no
later than November 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Sincerely,</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 6%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 44%">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">ABEONA THERAPEUTICS INC.</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">Neena M. Patil </TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">General Counsel</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Date:</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">UNDERSTOOD, AGREED TO AND</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">ACCEPTED WITH THE INTENTION</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">TO BE LEGALLY BOUND:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 6%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 41%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 28%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">F. CARSTEN THIEL, PhD</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Name:&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">F. Carsten Thiel, PhD</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Date:</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>tv507897_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Abeona
Therapeutics Announces CEO Transition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Dr. Carsten Thiel to Depart Company
Immediately; Dr. Jo&atilde;o Siffert Appointed Interim CEO</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEW YORK and CLEVELAND, Nov. 26, 2018 -- Abeona Therapeutics
Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for
life-threatening rare genetic diseases, today announced the immediate termination of its Chief Executive Officer, Dr. Carsten Thiel
due to personal misconduct that violated the Company&rsquo;s Code of Business Conduct and Ethics. The Company has appointed its
Head of Research &amp; Development and Chief Medical Officer, Dr. Jo&atilde;o Siffert, as Interim Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Thiel&rsquo;s termination follows an investigation by independent
members of the Company&rsquo;s Board of Directors and external counsel into allegations of misconduct towards colleagues that the
Board concluded violated the Company&rsquo;s Code of Business Conduct and Ethics and was inconsistent with its expectations for
Abeona&rsquo;s CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Thiel&rsquo;s termination is not related to the condition
of the Company&rsquo;s finances, operations or clinical programs, nor due to any disagreement with the Company regarding its management
of financial reporting, scientific data or other practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We expect all employees, regardless of title or responsibility,
to conduct themselves ethically and in accordance with company policies, and are committed to ensuring an environment of respect,
integrity and ethical conduct at Abeona,&rdquo; said Steven H. Rouhandeh, Chairman of the Board and Executive Chairman. &ldquo;The
Board is confident that Abeona is in good hands while we search for a new CEO as Jo&atilde;o&rsquo;s deep expertise in drug development
and gene therapy will ensure that the company continues operating effectively without interruption.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Siffert has successfully led multiple drug development programs
from pre-clinical to regulatory approvals in the U.S. and Europe, and has held several scientific leadership positions in biotech
and pharma, including programs in gene therapy. In 2017, Dr. Siffert was appointed to the Board of Directors of gene therapy developer
AveXis, which was subsequently acquired by Novartis. He served as Chief Medical Officer for Ceregene from 2007 to 2011, where he
was responsible for clinical development of adeno-associated viral (AAV2)-based gene therapies for Parkinson's and Alzheimer&rsquo;s
diseases. Dr. Siffert also led the R&amp;D and medical organizations at Avanir Pharmaceuticals and Avera Pharmaceuticals before
most recently guiding translational research, clinical development, regulatory, and medical affairs as Chief Scientific and Medical
Officer for Nestle Health Science.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board has formed a search committee to identify a permanent
successor, with the assistance of a leading executive search firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Abeona</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected
skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene
therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for
Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1)
for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and
ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing
a proprietary vector platform, AIM&trade;, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Abeona Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains certain statements that are forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, and that involve risks and uncertainties.&nbsp; These statements include statements about the ability of its
Interim Chief Executive Officer and the management team to lead the Company and deliver on key strategies, the market opportunities
for the Company&rsquo;s products and product candidates, and the&nbsp;Company&rsquo;s goals and objectives.&nbsp; We have attempted
to identify forward looking statements by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; and similar expressions (as well as
other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify
forward-looking statements.&nbsp;Actual results may differ materially from those indicated by such forward-looking statements as
a result of various important factors, numerous risks and uncertainties, including but not limited to continued interest in our
rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition, the ability to secure licenses
for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals,
the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting,
and other risks as may be detailed from time to time in the Company&rsquo;s Annual Reports on Form 10-K and quarterly reports on
Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission.&nbsp; The Company undertakes no obligation
to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this
presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities
laws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christine Silverstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SVP, Finance &amp; Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (646) 813-4707</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">csilverstein@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott Santiamo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director, Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (718) 344-5843</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ssantiamo@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "\ =L# 2(  A$! Q$!_\0
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M_M&_#WX#_LF^&&\9^(8=-N+F[O&@LHXWGN)!YS?,(T!(7@C<V!D8SFM_4/\
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M\^/K_5:+TCJWY_U_6ASOA7_@J-X"\%^&],T'1_AOJ]GI>FVZ6MM M[$=D:*
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M=Q  P-S'URQR37IM%:3Q-6I%Q;T?9)?DA*$4[A1117,6%%%% !1110 4444
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MQW26S3QK<R*72$N [*.I ZD"IYUS./5?K_PQ/.N9QZK]?^&)J*S([B[/B2:
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M!&^\C8(W+GG#9 /(YINB_:JHME96^_\ '73Y@Z#]LJD=DDK??^.NGS.2L_\
MDOFJ_P#8MVG_ *4W%9NG>&=*USXZ>+KG4=/M[^2UTW3UA^TQB0)O,^X@$8S\
MHYZ]?4UZ(FA6,>NRZRMN!J4MNMH\^XY,2LS*N,XX9F.<9YHMM"L;/6+W58;<
M)J%[''%<3;B2ZQ[M@QG QO;H.]/V+=K])-_G_F/V+=K])-_G_F</\*[.WTGQ
M1\0M.LH8[2P@U>-HK:%0L<9>UA9MJC@9//%4?ASX=TGQ'K?Q!O-8TRSU'4#X
M@FM7>\MTD80)%$(D^8'Y=N#CIS7HVGZ%8Z7?:C>6MN(KG4)5FNI Q/F.J! <
M$X'RJHXQTKS+Q%H-M)XRU>YUCP#>ZH99$%MJ&AN%%W%Y:C9<KYZ;F5@P^<;<
M!:RE3=.,;J]F_36_DS*=-TXQTO9OO;6_DS1_9[BM[?X?S169!M$U6_6$@Y&P
M7+A>?IBO2JXGX.^%[KPEX'AL[RS339Y;JYNOL,94K;+),[I%E>/E4J..*[>N
MC#Q<:,$UT1T8:+C1@FK:(\>^'EIX:\/R>-=1O[&PMTMO%<EO!,;56:)F%NL:
MKA25^=QC'0G-:OCK3[76OB]X%L=3MXKO3_LFH3I;W"!XWF41 $J>"55F(],D
MUTEQ\,_#%UXB_MV728WU/S4G,F]PC2KC;(8\["XP,,1D>M:/B+PEH_BVWBAU
M>PBO%A;?$S95XF(QE'!#*<=P16"H3]FX66Z?KK?4Q5"?LW"RW3]=;Z_TSA[+
M2[+0OC\D&EVD%C%=>'));N*UB6-79;E!&[!0/F^:09/./I1#I-CK_P =->75
M[.WOC9Z-9_88[J)9 B/)-YC*&'4L%!(],5V7AOP/H?A*2:32[!8+B<!9;F1W
MFGD Z!I')9ASW-<C\1-&2]\66ESJ'@^XUW34L]L6H:0_EWT$WF$E&(E1C$5(
M( SSNSUI2IN$4VNM[=/R^>VY,J;A!-K[5[=/R^>VY!\*M.L-)^(WQ,M-,ABM
MK..\L]L,"A41C;*S@ <#YBW'J37/>']'U77/&WQ NH_#_AS69EU@VS2ZW*ZS
M+$L$6Q !"XV8.>HR2>*ZSX1^$Y-!U'Q5J0T1O#ECJ=U";33I"AD5(X54R/L9
M@"[;CC)/KUKH-;^&OASQ!J3ZA=Z=MOY !)=6L\MM)* , .T3*7   PV>!41H
MRG3C96LV[>K?EY]B(T93I1LK6;=O5OR\^QC?"'01IG@_4-*N9=,O+==2O$^R
M:>YFMK9&E8FV^95^X692"*P?@G'X>T3P)X<N)[6SMM2O;^]M+6=;8>:\GGW!
MVA@N1\B-U(&!BO3]#T'3_#>FQZ?I=I'96<98K%$.,DDDGU))))/)S6-IGPS\
M,:/KS:S9Z3'#J!D>59 [E$=\AW1"=J,P)R5 )S6RHRCR-6T5ORV^[R-E1E'V
M;5O=5ORV^[R.5U#P[IFO?M![]2L;>_\ LWAJ-HDN8Q(J,;J0;@",9QQGW/K5
MKX>Z?;:+\3OB%I]A!'9V _L^X6U@4)&LCQ.'8*. 6V+G'7%=R-"L5UYM9%N/
M[3:V%F;C<<^4&+A<9Q]XDYQGFBTT*QL=6U#4X+<1WU^(UN9MQ/F",$)P3@8#
M'H.].-"TE+S;_!HI4+24M-V_P:/'K'2=4UOXI?$":+0O#VLRPW-M;AM;E=9(
MHOLR%50"%\*=S'J,DFNP^#.CRZ#HVN64D^ELJ:Q<,EGI$K206.X(Q@&57!#%
MCC&!N%;>O?#GP]XDU W]]I_^GE0C7=K/);3,HZ*SQLK,/8G%:F@^'=-\+Z>+
M'2K..RM=[2%(\_,S'+,2>22>I/-33P\H5.9^?XOT_4BEAY0J<S\_Q?I^K/*/
MA_\ #;P_XN\*^,H=0T^)IM1U_4EEO%C7SUQ<,%*.02I7&1Z')[U[-&NQ%7);
M QENI^M4M'T*Q\/P3PV%N+>.>XDNI%#%MTLC%G;DGJQ)QTJ_6U&DJ44K:F]&
MBJ44K:GG'[05G;W7PPOFG@BF,=U9E&D0-MS=0@XSTR"1]#76Z*VA6.J:AI.E
M06MI>6R1374%M (\+)N\LD@ '.Q_RJ[K&C6/B'2[G3M2M8[RQN%V2P2C*L*H
M^&/!>C>#89X](LOLWVA@TTC2/+)(0,+N=R6.!P 3QVH]G)5N=6LTO72_^8O9
MR5;VBM9I>NE_\S@/A#X5T/Q!X+U"]U?2;"^O[S5-0-_+=6Z.[,+J088D9X4+
MQVK:^ 4TMQ\'?"[3,SE;8QHS=3&KLL?_ (X%K2U+X3^%-5OY[RXTA!-<.9+A
M89I(HYV/5I$1@LA/^T#73V-C;Z;9P6EI!';6L"+'%#"H5$4# 4 <  =JRHT9
M4W%NVBMZ[:_AY[F5&C*FXMVT5O7;5Z>7GN2R1I-&T<B*\; JRL,@@]017FGP
M0T73[2Q\1W$%A;0W"^(-3A66.%5<1BX8! 0,[1@<=.*]-JAH^A6.@0W,5A;B
MW2XN);N4!BVZ61BSMR3U))QTK>5/FJ1GVN=$J?-4C/M?]#COA]_R4#XE?]A*
MU_\ 2*&L?X<>$=%U?Q-\1+^_TJTO[LZ_);>9=0K*1&((3M&X' )=LXZ\9Z5Z
M38:%8Z7?ZC>VMN(KG49%FNI-Q/F,J!%."<#"J!QCI1I>A6.BR7\EE;B![^Y-
MW<D,3YDI55+<GCA%&!QQ6*H?#S:V;?WW_P S%4/AYM;-O[[_ .9QGP,C6V\$
MW-I$-EM:ZMJ$$$8Z1QK=2!5'H *Y7X<>%= USX+7FH:SIEE<7UW_ &A/J%W<
M0(9O-$TVYBQ&0RXX/; Q7KNBZ%8^'[62WT^W%O#)/)<,H8MF21R[MR3U8D_C
M7/7GPC\(7U]=74VB0L]TS27$2R.L,SDY+/$&V,Q.>2I/-1["2C!63LFOR\O(
MS^KR48*R=DUK\O+R(O@K_P DC\'_ /8+M_\ T 5VE4]&T>S\/Z3::;I\(M[&
MTB6&&$,6V(HP!DDD\>M7:ZZ<7"$8OHCLI1<*<8OHD?/FGZ7_ ,)%\*]7UC3_
M  =X>.B:A!>7@-_>,]])EI"97D,1 ?.2!NXX&X8X]>^&=Q+>?#?PI<3R-+-+
MI-H[R.<EF,*$DGU)JG-\(/"$\EP7T9/*N-QEM1-*+=BQ)8^2&V9))YVYYKI]
M+TVVT73;33[*+R+.TA2"&($G8BJ%49/)P .M<M"C.G*\K;6_K1')AZ$Z<KRM
MM;^M$3REEC<H,N <#WKQGX:^#_"VO? >UNM<T^SE%Y93W&HW\D"&?S"SF60O
MM+;U.[!ZC'M7M-<=<?"'PA=74T[Z+&OGLS301RR)!*Q.27A5A&Q/NIZUI5IN
M<E))/1K7SM_D:UJ;G)223T:U\[>O8Y_XN2VUU^SSK4MC/+>6<FD(\%Q+G?+&
M0I5VR <D8)R!5WXT3QKI?A0&11YGB;2PG/WC]H4X'KP"?PKO+C3[6\L)+&>W
MBELY(S"]NZ QLA&"I7IC'&*Y2'X.^#X+BUN!HRO-:3QW%L\T\LA@=&#+Y>YC
ML ('RK@>U14I3E?EMJDONOZ]S.I1G*_+;5)?=?U[F3\=M/M]6T'PW97<2S6M
MSXCTZ&:)AD.C3 ,I]B"1^-=3IG@71]%\2S:WI]JMC<36BV<D-LBQPNJL65BH
M RPR1GTXK1UC0K'7DM4O[<7"VMS'>0@L1LEC;<C<$9P>QXJ_6JI+VCFUV_ V
M5%>T=1KM^%SPKPSHNK:[XL^(%TGA[PWK,O\ ;<EL\VM2NLRQ+#$(T $+C9MP
M1SR2>*[KX,Z4^A^#Y;!KK3[A8-0NPD>F2M)!;*9F;R Q53\A)7IQBM36OAIX
M;U_4I-1N].VW\N!+<VMQ+;22X& ':)E+@  8;/ K8T30]/\ #>FQ:?IEI'96
M462D,0P 222?<DDDD]2:QHT)4Y\S\_Q=^WZLPHX>5.?,_/\ %W[?JR\K!URI
M##U!I:SO#_A_3_"VDQ:9I=N+2QB9V2$,S8+N7;EB3RS,?QK1KM5[:[G<KVUW
M"BBBF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "\ =L# 2(  A$! Q$!_\0
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M_M&_#WX#_LF^&&\9^(8=-N+F[O&@LHXWGN)!YS?,(T!(7@C<V!D8SFM_4/\
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M\^/K_5:+TCJWY_U_6ASOA7_@J-X"\%^&],T'1_AOJ]GI>FVZ6MM M[$=D:*
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M=Q  P-S'URQR37IM%:3Q-6I%Q;T?9)?DA*$4[A1117,6%%%% !1110 4444
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MQW26S3QK<R*72$N [*.I ZD"IYUS./5?K_PQ/.N9QZK]?^&)J*S([B[/B2:
MW-F;$6J.MLN?M(D+L"[<XV$  <=0W-37>M:?I_G?:K^VMO)"M+YTRKL#9VEL
MGC.#C/H:?,NH^9;LNT5%;W,-Y"DT$J3Q,,K)&P93]"*KWFM:?I]Q%!=7UM;3
MRG$<<TRHS_0$\T[K<=UN7:*BM[J&\0O!-',BL4+1L& 8'!''<'BI*8Q:*Y3P
MW\3O#_B>ZU"WMM0MXYK2^:P"2SQYG<!2&C 8[E.\ >I!KI;N\M["%IKJ>.VA
M7K),X51^)J(SC)7B]"(SC-7B]":BJNGZI9ZM#YUE=P7D/_/2WD5U_,&DU#5K
M+28UDOKRWLXV. UQ*L8)],DU5U:Y5U:Y;HJ"WOK:[>1(+B*9H]N]8W#%<C(S
MCID<BH+_ %S3M*>-+W4+6S>0X1;B94+'VR>:+JUPNK7+U%1274,5LUP\T:6Z
MJ7:9F 0*!DDGIC'>N<\%_$?0_'&G6US87D*2SO*B6<LT?G_([*3M#'@["P]B
M#4N<4U%O5DN<4U%O5G445Q]QXU>Q^)-QHEW+:VVE0Z,FH&>8[&$AG>,@L3C;
MA1VZ]ZZJUO(+ZW2>VGCN(7&5DB<,I^A%$9QE=+H$9QE=+H3452U#6M/TG9]N
MO[6RWG"_:)ECW'T&3S5J.5)HU>-UD1AD,IR#^-5=;%75[#Z*SF\1:5'<10-J
M=FLTKM%'&;A SN#@J!GD@@Y'M6C0FGL":>P45S_CCQMIW@'07U74F/DK)'$(
MT90[EW5/E#$9QNR?8$UJ:=K%AK"NUA?6UZJ'#-;RK(%/O@\5//'FY;ZD\\>;
MDOJ7**H76OZ98W26USJ-I;W+_=AEG57;Z G)J\"& (.1573V*NGL+139)$AC
M:21E1%!9F8X  ZDFO/OA[X\O?''B'691J>D+I-K=7%G;:=;@O=2")]GGL^_&
MTD$@!,88<^L2J*,E%[LSE449*+W9Z'169IMQ=RZEJJ3W-G-!'*@@BM\^;$IC
M4D2Y)^8MDC 'RD4^Z\0:79*QN-2LX LGDL99T7#\?*<G[W(XZ\BJYE:[+YE:
M[-"BFHZR*&1@RL,AE.0:S=2\0V-EY]O]NM1?K$TB6S3+YAP,_=SG%-M+5C;2
MU9J45SOP[\07/BSP)H&LWBQI=7]E%<2K""$#,H)P"2<?C714HR4XJ2ZBC)3B
MI+9A15"37M,AOA92:C:)>-TMVG42'_@.<U?IW3V'=/8***HR:]IL5\+)]1M4
MO#TMVG42'_@.<T-I;@VEN7J*BNKJ&RMWGN)HX((QEY)6"JH]23THN+J&U5#/
M-'"'=8U,C!=S$X"C/4D]!1<+DM%0W%Y!9JC7$T<"NP13(X4%CT SW/I46GZO
M8ZLLC6-[;WJQML<V\JR!6]#@\&BZO8+J]BW15&_US3=+DCCO=0M;.20X1;B9
M4+?0$\U<1UD4,C!E89#*<@T76P76PZBBBF,**** "BBB@ HHHH **** /"_%
M_B*7X8ZY\1[6WR)-9L(M5TN->]W(1:N!ZGS# W_ JU/%GAV+X:Z#\.-2@P(_
M#-U!874HZ?9YT$$KG_@91OPKT+Q!X%T+Q5J>E:AJNG)>7FER>=9RL[*8FW*V
M< @-RBG!R.*OZ]H-AXFT>ZTO4[=;NPNDV30L2 PSGJ"".0.E>?\ 5Y>_K_A\
MM;_G;Y(\[ZM+W]?\/EK?\[?)'#_"<?V]K7C+Q:WS)J6HFRM&Z@VUJ#$I'LS^
M:?QJO9Z18:_\<O$_]K65O?-9Z38K9+=1+)L1FG,A4,.,L "17H&@Z#8>&=(M
M=+TRW6TL+9=D4*DD*,YZDDGDGDFL[Q'X!T'Q9=176I:>);R-/+2[AE>"=4SG
M:)(V5L9)XSCDU?L9<D5HVG=]FW>_XNYI[&7)%:-IW?9MWO\ B[G*?#.SM](^
M(7Q'T[3H([32X;NSECM[= D22O:J9-H' )PA/UK.\(^"=$\3>+/B@VI:;;7D
MMQJ2VC231*[+']EB.%)!QRQ/UQZ5Z1X>\+Z5X3LWM=(L8;&"1S*XB',CD %F
M)Y9L <DD\"I=-T*QTFZU"YM+<0S:A-]HN6#$^9)L5-W)X^55'&.E"H:14K:-
MO[[_ .8+#Z14K:-O[[_YGGOQ@TK^P?@];:;9.T_V*XTNW@>Z?)?9=0*I=@.2
M<#) ]>*E^$[1W6KZ_<:WG_A/%E\O48Y.D,&XF%;?_I@1R".6;);G@=[K>A6/
MB.P^Q:C;BYMO,CF\LL5^9'#H<@@\,H/X5%=^&=,OM>LM:EM1_:EG&\4-TCLC
M!&^\C8(W+GG#9 /(YINB_:JHME96^_\ '73Y@Z#]LJD=DDK??^.NGS.2L_\
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
